Payment overview · 2025
General Payments
$1,215.09
19 reported records · 7 companies
Healthcare provider profile · identity verified
Stanley Ng, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · NEW YORK, NY · NPI 1760671317
Verified facts
What the public records show
CMS Open Payments records show Stanley Ng, M.D. received $1,215.09 in general payments during 2025 across 19 reported records.
Amgen Inc. accounted for 58.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 137 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 150 claims for Farxiga by this doctor in 2024.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Vemlidy as an associated drug or biological on 782 records involving 554 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Vemlidy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Shingrix by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $705.34 | 58.0% | 8 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$178.45 | 14.7% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $139.60 | 11.5% | 2 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $90.54 | 7.5% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $61.54 | 5.1% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $22.38 | 1.8% | 1 | 2025 |
| Baxter Healthcare | Unresolved — no canonical attribution shown | $17.24 | 1.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,215.09 | 19 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $580.35 | 7 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $188.82 | 4 | 2025 |
Source payment records
|
|||||
| SYMPLICITY G3 Normalized: symplicity g3 |
Device | Medtronic, Inc. | $178.45 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $139.60 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $61.54 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $61.54 | 3 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $22.38 | 1 | 2025 |
Source payment records
|
|||||
| Hillrom - Vest System Model 105 Home Care Normalized: hillrom vest system model 105 home care |
Device | Baxter Healthcare | $17.24 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
137 | 77 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
150 | 32 |
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Vemlidy open payments reported associated product |
CMS Open Payments — General Payments 782 supporting records · 554 recipient NPIs · example record 1234350906 |
Vemlidy · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Vascepa | Icosapent Ethyl | 674 | 139 |
| Atorvastatin Calcium | Atorvastatin Calcium | 524 | 138 |
| Amlodipine Besylate | Amlodipine Besylate | 363 | 102 |
| Losartan Potassium | Losartan Potassium | 338 | 88 |
| Raloxifene Hcl | Raloxifene Hcl | 318 | 81 |
| Januvia | Sitagliptin Phosphate | 256 | 55 |
| Metoprolol Succinate | Metoprolol Succinate | 186 | 49 |
| Pravastatin Sodium | Pravastatin Sodium | 161 | 40 |
| Ammonium Lactate | Ammonium Lactate | 160 | 59 |
| Farxiga | Dapagliflozin Propanediol | 150 | 32 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 146 | 43 |
| Celecoxib | Celecoxib | 143 | 45 |
| Tamsulosin Hcl | Tamsulosin Hcl | 143 | 40 |
| Famotidine | Famotidine | 139 | 41 |
| Prolia | Denosumab | 137 | 77 |
| Simvastatin | Simvastatin | 134 | 35 |
| Metformin Hcl | Metformin Hcl | 128 | 34 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 122 | 32 |
| Pioglitazone Hcl | Pioglitazone Hcl | 120 | 26 |
| Montelukast Sodium | Montelukast Sodium | 117 | 35 |
| Valsartan | Valsartan | 116 | 32 |
| Jardiance | Empagliflozin | 112 | 18 |
| Atenolol | Atenolol | 99 | 29 |
| Finasteride | Finasteride | 93 | 27 |
| Clopidogrel | Clopidogrel Bisulfate | 89 | 24 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 89 | 24 |
| Levothyroxine Sodium | Levothyroxine Sodium | 86 | 21 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 77 | 21 |
| Donepezil Hcl | Donepezil Hcl | 74 | 18 |
| Eliquis | Apixaban | 71 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 68 | 22 |
| Meloxicam | Meloxicam | 63 | 23 |
| Propranolol Hcl | Propranolol Hcl | 63 | 17 |
| Omeprazole | Omeprazole | 62 | 21 |
| Fluticasone Propionate | Fluticasone Propionate | 59 | 18 |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 53 | 14 |
| Tradjenta | Linagliptin | 53 | 11 |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 51 | 19 |
| Azelastine Hcl | Azelastine Hcl | 46 | 16 |
| Icosapent Ethyl | Icosapent Ethyl | 40 | 14 |
| Linzess | Linaclotide | 39 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 38 | suppressed |
| Allopurinol | Allopurinol | 37 | suppressed |
| Gabapentin | Gabapentin | 36 | suppressed |
| Hydrocortisone | Hydrocortisone | 35 | 14 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 33 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 32 | 14 |
| Hydrochlorothiazide | Hydrochlorothiazide | 32 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 32 | 12 |
| Mometasone Furoate | Mometasone Furoate | 31 | 17 |
| Carvedilol | Carvedilol | 30 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 30 | suppressed |
| Acarbose | Acarbose | 29 | suppressed |
| Furosemide | Furosemide | 27 | 12 |
| Ketoconazole | Ketoconazole | 27 | 11 |
| Quetiapine Fumarate | Quetiapine Fumarate | 23 | suppressed |
| Torsemide | Torsemide | 23 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 22 | suppressed |
| Potassium Chloride | Potassium Chloride | 21 | suppressed |
| Repaglinide | Repaglinide | 21 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 20 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 19 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 18 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 18 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 18 | suppressed |
| Lisinopril | Lisinopril | 18 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 18 | suppressed |
| Xarelto | Rivaroxaban | 18 | suppressed |
| Jentadueto | Linagliptin/Metformin Hcl | 17 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 17 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 16 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 16 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 15 | suppressed |
| Clonazepam | Clonazepam | 15 | suppressed |
| Loperamide | Loperamide Hcl | 15 | suppressed |
| Vemlidy | Tenofovir Alafenamide | 15 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 14 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 14 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 14 | 12 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 13 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 13 | suppressed |
| Glipizide Er | Glipizide | 13 | suppressed |
| Humalog Mix 75-25 | Insulin Lispro Protamin/Lispro | 13 | suppressed |
| Nifedipine Er | Nifedipine | 13 | suppressed |
| Amlodipine-Atorvastatin | Amlodipine/Atorvastatin | 12 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 12 | suppressed |
| Glipizide | Glipizide | 12 | suppressed |
| Levetiracetam | Levetiracetam | 12 | suppressed |
| Lovastatin | Lovastatin | 12 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 12 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 12 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 11 | suppressed |
| Myrbetriq | Mirabegron | 11 | suppressed |
| Procto-Med Hc | Hydrocortisone | 11 | suppressed |
| Spironolactone | Spironolactone | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,215.09 · 19 records | Amgen Inc. | AREXVY, BREZTRI, Hillrom - Vest System Model 105 Home Care, OTEZLA, Ozempic, REPATHA, Rybelsus, SYMPLICITY G3 | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with Amgen Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error